By Neena Bhandari

Sydney, 14.08.2025 (Oncology Republic): The real-world data space is increasingly recognising the value of qualitative data that captures patient-specific values and experiences. It can help researchers and policy makers develop better ways for disease prevention and cure, and enhance quality of care, but to harness its value, there is a need for stronger infrastructure, governance, and interoperability frameworks.

A recent New England Journal of Medicine Perspective by former FDA Commissioner Scott Gottlieb and colleagues highlights the growing significance of real-world data (RWD) in clinical research, regulatory decisions, and health system improvement. Despite its promise, major barriers, including fragmented data systems, variable quality, and limited linkage between real-world evidence (RWE) and clinical decision-making, restrict its full potential, they say.

Sallie Pearson, Professor of Health Systems and director of NHMRC Centre of Research Excellence in Medicines Intelligence at UNSW said RWD had the potential to be a reliable complement to randomised controlled trials.

Continue Reading on Oncology Republic

© Copyright Neena Bhandari. All rights reserved. Republication, copying or using information from neenabhandari.com content is expressly prohibited without the permission of the writer and the media outlet syndicating or publishing the article.